Understanding MRD
Why is Measurable Residual Disease the key to better outcomes?
Measurable residual disease, or MRD, refers to molecular signs of cancer that may remain after treatment, even when disease is not visible through conventional imaging.
At Altum Sequencing, MRD monitoring is performed through ctDNA analysis using liquid biopsy and NGS-based detection, helping clinical teams follow molecular disease dynamics over time.
Measurable Residual Disease (MRD)
Cancer cells that survive treatment are undetectable by scans, but measurable at the DNA level in the bloodstream. Their presence predicts relapse with high accuracy.
The Quantification of MRD is one of the most powerful tools in precision oncology
MRD status at key timepoints, post-surgery, post-chemo, during surveillance, is the strongest independent predictor of long-term outcomes across most solid tumors and hematological malignancies.
Patient-specific, editable, adaptable, cost-efficient
Altum Sequencing's liquid biopsy approach is non-invasive, patient-specific, and designed for serial monitoring, giving a dynamic picture of tumour evolution that static imaging simply cannot provide.
"Our objective at Altum Sequencing is to bring precision and anticipation to oncology care through ultra-sensitive ctDNA analysis. One patient, one molecule at a time."
Dr. Joaquin Martinez
Chairman and Co-Founder
How We Do It
From Liquid Biopsy Samples to Clinical Decisions.
Data Platform as a Core
Our platform integrates tumor genomic profiling, liquid biopsy sample processing, ultra-sensitive NGS and AI-driven analysis to generate structured molecular insights for diagnosis, MRD monitoring, clonal evolution and longitudinal follow-up. Every step is validated, reproducible, and built for regulatory compliance across solid tumors and hematological malignancies
1
Clinical & biological samples
Tumor tissue or liquid biopsy are collected for baseline profiling
2
Biomarker selection
Tumor specific NGS-based panels identifie relevant alterations and supports tumor-informed monitoring strategies.
3
Liquid biopsy & ctDNA extraction
ctDNA isolation optimized for maximum yield
4
NGS library preparation
Optimized library preparation and molecular barcoding support sensitive detection of low-frequency variants.
5
AI-driven analysis
Proprietary bioinformatics helps distinguish true tumor-derived signals from technical noise, germline variants and biological background.
6
Structured clinical report
Results are delivered in a clear report designed to support clinical interpretation, longitudinal follow-up and research workflows.
Traditional tissue biopsies are a snapshot: invasive, expensive, and limited to the sampled region. Liquid biopsy captures a real-time, whole-body view of tumour biology through a simple blood draw. As cancer cells die, they shed fragments of their DNA into the bloodstream. We capture, amplify, and sequence these fragments with unmatched sensitivity.
​
Unlike imaging, liquid biopsy detects cancer at the molecular level, before it becomes visible. Unlike protein biomarkers, it is tumour-specific and highly sensitive. And unlike tissue biopsy, it can be repeated serially to track tumour evolution over time.
​
Liquid biopsy complements tissue biopsy, imaging and standard biomarkers by adding a molecular view of disease dynamics during treatment and follow-up.
Blood
Primary source plasma cfDNA
CSF
CNS & brain tumours
Saliva
Head & neck cancers
Urine
Urological malignancies
Liquid Biopsy & ctDNA Analysis
Patented Algorithm
Detecting low-frequency ctDNA requires more than sequencing depth. Altum Sequencing’s bioinformatics workflow is designed to reduce technical noise, sequencing artefacts, germline background and non-tumor signals such as clonal hematopoiesis.
By combining molecular barcoding, error suppression and AI-supported variant scoring, our platform helps identify tumor-derived variants with high confidence in selected monitoring applications.
Data Platform
Altum ATLAS connects molecular results, assay metadata and longitudinal patient monitoring into a structured data environment designed for clinical interpretation, research and scalable implementation. The platform supports report generation, longitudinal ctDNA visualization, cohort-level analysis and contextualization of molecular findings across selected cancer settings.
Longitudinal tracking
Visualizes molecular dynamics across serial samples and treatment timepoints.
Structured reporting
Generates clear reports for clinical teams, molecular boards and research programs.
Cohort-level insights
Supports benchmarking and exploratory analyses across selected indications and study cohorts.
Secure data handling
Designed to support de-identified, GDPR-aligned data workflows where applicable.
Discover our TESTS — click to explore
The Altum Sequencing technology stack in practice.
Different clinical questions require different molecular strategies. Altum Sequencing’s products translate our liquid biopsy, NGS and bioinformatics platform into dedicated solutions for profiling, monitoring and longitudinal interpretation.
.png)
Comprehensive NGS panels for tumor characterization, actionable alteration detection and biomarker selection.
​
.png)
Personalized ctDNA tracking based on patient-specific tumor variants for longitudinal MRD assessment.
​
.png)
ctDNA analysis designed to identify emerging variants, resistance mechanisms and tumor evolution without prior tumor profiling.
.png)
Simultaneous molecular monitoring + therapy-derived or allogeneic molecular signals follow-up.
​
